Immune Therapeutics, Inc., together with its subsidiaries, focuses on the development and commercialization of therapeutic treatments for cancer, human immunodeficiency virus (HIV)/AIDS, and autoimmune and immune disorders in the United States and internationally. It develops methionine enkephalin IRT-101, a small synthetic pentapeptide; and low-dose naltrexone IRT-103, an opioid receptor antagonist that stimulates and/or regulates the immune system to treat a range of autoimmune diseases, including multiple sclerosis; immune disorders, such as Crohn's disease and cancer; and viral infections comprising HIV/AIDS. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone888-613-8802
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$110,000.00
Profitability
Miscellaneous
Employees4
Next Earnings Date4/21/2020 (Estimated)
OptionableNot Optionable
Immune Therapeutics (OTCMKTS:IMUN) Frequently Asked Questions
What is Immune Therapeutics' stock symbol?
Immune Therapeutics trades on the OTCMKTS under the ticker symbol "IMUN."
When is Immune Therapeutics' next earnings date?
Has Immune Therapeutics been receiving favorable news coverage?
Headlines about IMUN stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immune Therapeutics earned a news impact score of -1.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Immune Therapeutics.
Who are some of Immune Therapeutics' key competitors?
Some companies that are related to Immune Therapeutics include Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM), Mereo BioPharma Group (MREO), Myrexis (MYRX), NeuroVive Pharmaceutical (NEVPF), Pivotal Therapeutics (PVTTF) and Poniard Pharmaceuticals (PARD).
What other stocks do shareholders of Immune Therapeutics own?
Who are Immune Therapeutics' key executives?
Immune Therapeutics' management team includes the folowing people:
- Ms. Noreen Griffin, Founder, CEO, Pres & Director (Age 66)
- Mr. Peter Aronstam, Chief Financial Officer (Age 67)
- Dr. Fengping Shan, Chief Science Officer (Age 60)
- Dr. Angus George Dalgleish, Chief Medical Officer and Director of R&D (Age 69)
- Dr. Joseph M. Fortunak, VP of Global R&D and Chemical Devel. (Age 64)
How do I buy shares of Immune Therapeutics?
Shares of IMUN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Immune Therapeutics' stock price today?
One share of IMUN stock can currently be purchased for approximately $0.01.
How big of a company is Immune Therapeutics?
What is Immune Therapeutics' official website?
How can I contact Immune Therapeutics?
Immune Therapeutics' mailing address is 37 NORTH ORANGE AVENUE SUITE 800M, ORLANDO FL, 32801. The company can be reached via phone at 888-613-8802.
MarketBeat Community Rating for Immune Therapeutics (OTCMKTS IMUN)
MarketBeat's community ratings are surveys of what our community members think about Immune Therapeutics and other stocks. Vote "Outperform" if you believe IMUN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMUN will underperform the S&P 500 over the long term. You may vote once every thirty days.
